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Z-drugs (i.e., zopiclone, zaleplon and zolpidem) first
appeared on the market as a substitute for benzodiaze-
pines (BZDs), purportedly having a lower risk of addiction
due to improved pharmacokinetics. However, recent
research has shown they may be similar to BZDs in terms
of cognitive, behavioral and psychomotor performance1;
risk of dependence2; and mortality.3 Nevertheless, this
scientific knowledge has not seemed to influence the rate
of Zolpidem consumption, especially in developing coun-
tries,4 where regulatory measures may be more vulnerable
to the influence of the pharmaceutical industry. In light of
this research, the Food and Drug Administration (FDA)
released two Drug Safety Communications (DSCs) in 2013
regarding products containing Zolpidem, describing the risk
of next-day impairment and recommending lower starting
doses, particularly for women.5
Following this FDA action, a number of studies reported
reductions in the prescribed dose,6 reducing the risks of
adverse effects. However, other research has shown that
more than 70% of general practitioners do not recognize
or even evaluate the side effects of these hypnotics,7 and
that the beliefs of clinicians and patients about the drugs’
safety do not seem to keep pace with advances in research,
producing a gap between scientific evidence and clinical
practice. Education, backed by legislation, about the effects
of the chronic use of these medications is extremely
important to ensure appropriate prescription and reduce
misuse. In Brazil, the regulations for prescribing Z-drugs
are weak: The risk of dependence is explicitly stated on the
leaflet accompanying Zolpidem although it is not classified
under the same regulations as BZDs. A standard prescrip-
tion is used rather than the specific blue one required for
BZDs, and their packaging presents neither the customary
black stripe found on the most strictly controlled medica-
tions nor the words ‘‘the abuse of this medicine can cause
dependence,’’ as can be found on BZDs. The packaging
features only a red stripe, typical of medications such as
antiepileptics or antidepressants, which may lead consu-
mers to believe the medicine has a different status than
BZDs and carries little or no dependence risk or other
negative effects.
This lack of control and medical guidance could
potentially contribute to dependence problems or other
consequences. Although there is still a lack of evi-
dence about the effect size for outcomes such as demen-
tia, infections or cancer, as well as the heterogeneity
of risk among different Z-drugs, there is mounting
evidence that Z-drugs are similar to BZDs, at least with
respect to motor vehicle accidents, falls and fractures.8
Therefore, it is urgently necessary to disseminate informa-
tion about the similarities between BZDs and Z-drugs,
since they have been shown to cause similar adverse
effects and dose escalation1 due to tolerance, and thereby
challenge the belief among professionals and patients that
Z-drugs present less risk.7 In addition, further research into
the influence of regulation on the consumption of hypnotics
is required. Policy makers must be made more aware
of Z-drugs’ potential for dependence and be encouraged
to adopt measures such as those of the FDA, bringing
regulations in line with those of BZDs in order to increase
patient and physician knowledge about this issue and
reduce potential harm.
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